WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
0
0.00%
-1.01%
-0.97%
Apr 2025
Baroda BNP Paribas Small Cap Fund Direct - Growth
30000
2.14%
0.95%
1.13%
Apr 2025
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth
0
0.00%
-0.92%
0.00%
Apr 2025
Samco Multi Asset Allocation Fund Direct-Growth
1831
0.61%
0.61%
0.61%
Apr 2025
ICICI Prudential Smallcap Fund Direct Plan-Growth
35322
0.40%
-0.61%
-0.80%
Apr 2025
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth
55021
0.90%
-0.15%
-0.81%
Apr 2025
Bandhan Small Cap Fund Direct-Growth
14422
0.12%
-0.09%
-0.22%
Apr 2025
Bajaj Finserv ELSS Tax Saver Fund Direct-Growth
500
0.88%
-0.09%
-0.13%
Apr 2025
Navi Nifty 500 Multicap 50:25:25 Index Fund Direct-Growth
0
0.00%
-0.08%
-0.06%
Apr 2025
Bandhan Aggressive Hybrid Fund Direct-Growth
15080
1.55%
-0.06%
0.07%
Apr 2025
Nippon India Small Cap Fund Direct- Growth
658075
0.98%
-0.04%
0.11%
Apr 2025
Baroda BNP Paribas Manufacturing Fund Direct - Growth
34200
2.36%
-0.04%
0.37%
Apr 2025
Nippon India Nifty 500 Equal Weight Index Fund Direct-Growth
918
0.20%
-0.01%
-0.05%
Apr 2025
Edelweiss Nifty500 Multicap Momentum Quality 50 Index Fund Direct-Growth
1284
0.54%
-0.01%
0.54%
Apr 2025
UTI Nifty Midsmallcap 400 Momentum Quality 100 Index Fund Direct-Growth
214
0.41%
-0.01%
0.20%
Apr 2025
Samco Multi Cap Fund Direct-Growth
5189
1.30%
0.01%
1.30%
Apr 2025
Bandhan Innovation Fund Direct-Growth
66823
4.05%
0.01%
0.50%
Apr 2025
Nippon India Pharma Fund Direct-Growth
64078
0.67%
-0.01%
0.11%
Apr 2025
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
2911
0.31%
0.00%
0.04%
Apr 2025
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth
7191
0.31%
0.00%
0.04%
Apr 2025
ICICI Prudential Nifty 500 Index Fund Direct-Growth
7
0.03%
0.00%
0.00%
Apr 2025
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
1595
0.31%
0.00%
0.04%
Apr 2025
About AstraZeneca Pharma
AstraZeneca Pharma India Limited is a biopharmaceutical company incorporated in 1979. It manufactures, distributes, and markets pharmaceutical products, focusing on cardiovascular, renal and metabolism, oncology, and respiratory diseases. The company operates in the healthcare segment and provides clinical trial services to an overseas group company. Key products include Forxiga for heart failure and chronic kidney disease, Imfinzi for biliary tract carcinoma, Lynparza for breast cancer, and oral antidiabetic drugs like Onglyza and Kombiglyze. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is indirectly owned by AstraZeneca PLC, United Kingdom. The company has manufacturing facilities in Bangalore and has expanded its R&D presence in India.